论文部分内容阅读
目的观察周剂量伊立替康联合顺铂一线治疗广泛期小细胞肺癌(SCLC)的疗效及不良反应。方法 42例经病理或细胞学诊断为广泛期SCLC患者接受伊立替康60mg/m2第1、8、15天,顺铂25mg/m2第1-3天,每28天为1个周期,治疗2个周期评价疗效,每周期评价不良反应。结果 42例入选患者均可评价疗效。获完全缓解(CR)3例,部分缓解(PR)34例,总有效率(CR+PR)为88.09%。所有患者中位疾病进展时间为225d,中位生存时间401d。主要不良反应为Ⅲ/Ⅳ度中性粒细胞下降(19例,45.2%),腹泻(7例,16.7%)和恶心、呕吐(13例,31.0%)等。结论周剂量伊立替康联合顺铂一线治疗广泛期SCLC安全、有效,可作为一线化疗方案的选择。
Objective To observe the curative effect and side effects of first-line irinotecan plus cisplatin in the treatment of extensive-stage small cell lung cancer (SCLC). Methods Forty-two patients with idiopathic SCLC who were diagnosed as extensive-stage SCLC by pathology or cytology were treated with irinotecan 60 mg / m2 for days 1, 8 and 15 and cisplatin 25 mg / m2 for days 1-3 and every 28 days for 1 cycle. Treatment 2 Evaluation of the efficacy of a cycle, weekly evaluation of adverse reactions. Results 42 patients were selected for evaluation of efficacy. Three patients had complete remission (CR), 34 had partial remission (PR), and the total effective rate (CR + PR) was 88.09%. The median time to progression for all patients was 225 days and the median survival time was 401 days. The main adverse reactions were grade Ⅲ / Ⅳ neutropenia (19 cases, 45.2%), diarrhea (7 cases, 16.7%) and nausea and vomiting (13 cases, 31.0%). Conclusion Weekly dose of irinotecan plus cisplatin in the first-line treatment of SCLC is safe and effective and can be used as a first-line chemotherapy option.